Mark Eisner
EVP and Chief Medical Officer at Vir Biotechnology, Inc. (VIR) since June 2024
Mark Eisner has filed 29 insider reports with the SEC since October 2021, as director at Jade Biosciences, Inc. (JBIO), director at Zura Bio Ltd (ZURA) and EVP and Chief Medical Officer at Vir Biotechnology, Inc. (VIR) and at 1 more company. In the last 12 months Mark Eisner sold $49.5K of stock on the open market. The latest filing, on June 27, 2026, reports grant or award at Jade Biosciences, Inc. (JBIO).
- Filings
- 29
- Companies
- 4
- Bought on market
- None
- Sold on market
- $695K
Companies where Mark Eisner is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences, Inc. | Directorsince June 2026 | $15.07 | Jun 27, 2026 | ||||
| ZURA Zura Bio Ltd | Directorsince February 2026 | $4.09 | Jun 22, 2026 | ||||
| VIR Vir Biotechnology, Inc. | EVP and Chief Medical Officersince June 2024 | 154,024 | $106K | $12.21 | Feb 26, 2026 | ||
| KYNB Fibrogen Inc | Officer | 159,917 | $588K | $3.73 | Sep 8, 2023 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 25, 2026JBIOSEC Form 4 filed by Director Eisner MarkForm 4Grant or award
- Jun 25, 2026JBIOMark Eisner became an insiderForm 3New insider
- Jun 17, 2026ZURASEC Form 4 filed by Director Eisner MarkForm 4Grant or award
- Feb 25, 2026-$34KVIREVP and Chief Medical Officer Eisner Mark sold $33,955 worth of shares (3,505 units at $9.69), decreasing direct ownership by 2% to 154,024 unitsForm 4Open-market sale10b5-1 plan
- Feb 21, 2026ZURASEC Form 4 filed by Director Eisner MarkForm 4Grant or award
- Feb 21, 2026ZURAMark Eisner became an insiderForm 3New insider
- Feb 23, 2026-$15.6KVIREVP and Chief Medical Officer Eisner Mark was granted 55,000 shares and sold $15,569 worth of shares (2,089 units at $7.45), increasing direct ownership by 51% to 157,529 unitsForm 4Grant or awardOpen-market sale10b5-1 plan
- Jul 17, 2025-$56.8KVIREVP and Chief Medical Officer Eisner Mark sold $56,791 worth of shares (10,382 units at $5.47), decreasing direct ownership by 9% to 104,618 unitsForm 4Open-market sale10b5-1 plan
- Jul 17, 2025~$19.4KVIRMark Eisner plans to sell 3,586 shares (~$19.4K)Form 144Planned sale10b5-1 plan
- Feb 22, 2025VIREVP and Chief Medical Officer Eisner Mark was granted 40,000 shares, increasing direct ownership by 53% to 115,000 unitsForm 4Grant or award
- Jul 15, 2024VIREVP and Chief Medical Officer Eisner Mark was granted 75,000 sharesForm 4Grant or award
- Jun 3, 2024VIRNew insider Eisner Mark claimed no ownership of stock in the companyForm 3New insider
- Sep 6, 2023KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 1,860 shares, decreasing direct ownership by 1% to 159,917 unitsForm 4Shares withheld for taxes or exercise price
- Sep 1, 2023KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 1,085 shares, decreasing direct ownership by 0.67% to 161,777 unitsForm 4Shares withheld for taxes or exercise price
- Jun 7, 2023-$34.8KKYNBSEC Form 4 filed by Eisner MarkForm 4Open-market sale
- Jun 2, 2023-$20.5KKYNBSEC Form 4 filed by Eisner MarkForm 4Open-market sale
- Apr 4, 2023-$172KKYNBSEC Form 4 filed by Eisner MarkForm 4Open-market sale
- Mar 10, 2023-$361KKYNBSEC Form 4: Eisner Mark was granted 20,183 shares and sold $360,572 worth of shares (17,503 units at $20.60), increasing direct ownership by 2% to 175,176 unitsForm 4Grant or awardOpen-market sale
- Feb 21, 2023KYNBSEC Form 4: Eisner Mark was granted 32,500 shares, increasing direct ownership by 23% to 173,683 unitsForm 4Grant or award
- Dec 1, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 1,084 shares, decreasing direct ownership by 0.76% to 141,183 unitsForm 4Shares withheld for taxes or exercise price
- Sep 30, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 6,777 shares, decreasing direct ownership by 5% to 142,267 unitsForm 4Shares withheld for taxes or exercise price
- Sep 1, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 756 shares, decreasing direct ownership by 0.50% to 149,044 unitsForm 4Shares withheld for taxes or exercise price
- Jun 1, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 1,141 shares, decreasing direct ownership by 0.76% to 149,800 unitsForm 4Shares withheld for taxes or exercise price
- Mar 31, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 6,442 shares, decreasing direct ownership by 4% to 150,941 unitsForm 4Shares withheld for taxes or exercise price
- Mar 1, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 756 shares, decreasing direct ownership by 0.48% to 157,383 unitsForm 4Shares withheld for taxes or exercise price
- Feb 14, 2022KYNBSEC Form 4: Eisner Mark was granted 60,000 shares, increasing direct ownership by 61% to 158,139 unitsForm 4Grant or award
- Jan 3, 2022KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 7,043 shares, decreasing direct ownership by 7% to 98,139 unitsForm 4Shares withheld for taxes or exercise price
- Dec 1, 2021KYNBSEC Form 4: Eisner Mark covered exercise/tax liability with 4,338 shares, decreasing direct ownership by 4% to 105,182 unitsForm 4Shares withheld for taxes or exercise price
- Oct 4, 2021KYNBSEC Form 4: Eisner Mark was granted 74,520 shares, increasing direct ownership by 213% to 109,520 unitsForm 4Grant or award
Compare Mark Eisner with
- Mark Eisner vs Vanina de Verneuil1 shared
- Mark Eisner vs Thane Wettig1 shared
- Mark Eisner vs David DeLucia1 shared
- Mark Eisner vs Robert J More1 shared
- Mark Eisner vs Saira Ramasastry1 shared
- Mark Eisner vs Jennifer Jarrett1 shared
Other insiders at the same companies
- Vanina de VerneuilVIR
- Thane WettigKYNB
- David DeLuciaKYNB
- Robert J MoreVIR
- Saira RamasastryVIR
- Marlyn Teresa MathewZURA
- Jennifer JarrettZURA
- Parvinder ThiaraZURA
- Ajay NirulaZURA
- Steven J SchochZURA
- Amit MunshiZURA
- Daniel J. BeckerZURA
- Maykin HoKYNB
- Jeffrey L EdwardsKYNB
- Michael KauffmanKYNB
- James A SchoeneckKYNB
Questions about Mark Eisner
- What is Mark Eisner's role at Vir Biotechnology, Inc.?
- Mark Eisner reports to the SEC as EVP and Chief Medical Officer at Vir Biotechnology, Inc. (VIR), according to the latest filing on February 26, 2026. Mark Eisner has also filed as director at Jade Biosciences, Inc. (JBIO), director at Zura Bio Ltd (ZURA) and officer at Fibrogen Inc (KYNB).
- How many shares does Mark Eisner own?
- After the latest filing that states it, Mark Eisner directly owned 154,024 shares of Vir Biotechnology, Inc. (VIR) and 159,917 shares of Fibrogen Inc (KYNB). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Mark Eisner bought or sold stock recently?
- The most recent open-market sale was on February 25, 2026: sold 3,505 shares of Vir Biotechnology, Inc. (VIR) for $34K at an average of $9.69.
- How do I get alerts when Mark Eisner files?
- Follow Mark Eisner on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark Eisner (SEC CIK 0001834161). Totals count each trade once, skipping amendments whose original is on file, from Oct 6, 2021 on. View on SEC EDGAR